Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth.

Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, Maillet M, York AJ, Lorenz JN, Zimmermann WH, Meloche S, Molkentin JD.

Circ Res. 2011 Jan 21;108(2):176-83. doi: 10.1161/CIRCRESAHA.110.231514. Epub 2010 Dec 2.

3.

A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.

Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ.

Nat Med. 2009 Jan;15(1):75-83. doi: 10.1038/nm.1893. Epub 2008 Dec 7.

PMID:
19060905
4.

Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14074-9. Epub 2007 Aug 20.

5.

DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.

Maillet M, Purcell NH, Sargent MA, York AJ, Bueno OF, Molkentin JD.

J Biol Chem. 2008 Nov 7;283(45):31246-55. doi: 10.1074/jbc.M806085200. Epub 2008 Aug 27.

6.

The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD.

EMBO J. 2000 Dec 1;19(23):6341-50.

7.

Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction.

Ulm S, Liu W, Zi M, Tsui H, Chowdhury SK, Endo S, Satoh Y, Prehar S, Wang R, Cartwright EJ, Wang X.

J Mol Cell Cardiol. 2014 Jul;72:104-16. doi: 10.1016/j.yjmcc.2014.03.002. Epub 2014 Mar 12.

8.

IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.

Sbroggiò M, Carnevale D, Bertero A, Cifelli G, De Blasio E, Mascio G, Hirsch E, Bahou WF, Turco E, Silengo L, Brancaccio M, Lembo G, Tarone G.

Cardiovasc Res. 2011 Aug 1;91(3):456-64. doi: 10.1093/cvr/cvr103. Epub 2011 Apr 14.

9.

Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Ruppert C, Deiss K, Herrmann S, Vidal M, Oezkur M, Gorski A, Weidemann F, Lohse MJ, Lorenz K.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7440-5. doi: 10.1073/pnas.1221999110. Epub 2013 Apr 15.

10.

Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation.

Chung E, Yeung F, Leinwand LA.

J Appl Physiol (1985). 2012 May;112(9):1564-75. doi: 10.1152/japplphysiol.00027.2012. Epub 2012 Feb 16.

11.

Regulator of G-Protein Signaling 10 Negatively Regulates Cardiac Remodeling by Blocking Mitogen-Activated Protein Kinase-Extracellular Signal-Regulated Protein Kinase 1/2 Signaling.

Miao R, Lu Y, Xing X, Li Y, Huang Z, Zhong H, Huang Y, Chen AF, Tang X, Li H, Cai J, Yuan H.

Hypertension. 2016 Jan;67(1):86-98. doi: 10.1161/HYPERTENSIONAHA.115.05957. Epub 2015 Nov 16. Review.

12.

Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction.

Zhang Y, Zhang XF, Gao L, Liu Y, Jiang DS, Chen K, Yang Q, Fan GC, Zhang XD, Huang C.

Biochim Biophys Acta. 2014 Feb;1842(2):232-44. doi: 10.1016/j.bbadis.2013.11.018. Epub 2013 Nov 23.

13.

Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.

Liu L, Zhao X, Pierre SV, Askari A.

Am J Physiol Cell Physiol. 2007 Nov;293(5):C1489-97. Epub 2007 Aug 29.

14.

DUSP8 Regulates Cardiac Ventricular Remodeling by Altering ERK1/2 Signaling.

Liu R, van Berlo JH, York AJ, Vagnozzi RJ, Maillet M, Molkentin JD.

Circ Res. 2016 Jul 8;119(2):249-60. doi: 10.1161/CIRCRESAHA.115.308238. Epub 2016 May 25.

15.

MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo.

Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouysségur J, Pagès G, De Windt LJ, Doevendans PA, Molkentin JD.

Circulation. 2004 Apr 27;109(16):1938-41. Epub 2004 Apr 19.

16.

Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.

Taglieri DM, Monasky MM, Knezevic I, Sheehan KA, Lei M, Wang X, Chernoff J, Wolska BM, Ke Y, Solaro RJ.

J Mol Cell Cardiol. 2011 Dec;51(6):988-96. doi: 10.1016/j.yjmcc.2011.09.016. Epub 2011 Sep 24.

17.

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload.

Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ.

Circulation. 2004 Aug 10;110(6):718-23. Epub 2004 Aug 2.

18.

Src is required for mechanical stretch-induced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent β-arrestin2 pathways.

Wang S, Gong H, Jiang G, Ye Y, Wu J, You J, Zhang G, Sun A, Komuro I, Ge J, Zou Y.

PLoS One. 2014 Apr 3;9(4):e92926. doi: 10.1371/journal.pone.0092926. eCollection 2014.

19.

RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.

Gailhouste L, Ezan F, Bessard A, Frémin C, Rageul J, Langouët S, Baffet G.

Int J Cancer. 2010 Mar 15;126(6):1367-77. doi: 10.1002/ijc.24950.

20.

Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.

Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.

Oncogene. 2007 Feb 8;26(6):813-21. Epub 2006 Aug 7.

PMID:
16909118

Supplemental Content

Support Center